The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck (RESCUE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05808920 |
|
Recruitment Status :
Recruiting
First Posted : April 12, 2023
Last Update Posted : February 7, 2024
|
Sponsor:
Royal Marsden NHS Foundation Trust
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and neck squamous cell carcinoma (SCC).
Additionally, the RESCUE study will contain an exploratory molecular analysis of consenting patients to assess the relationship between cancer genomics, previous radiotherapy, and recurrence in head and neck cancer.
| Condition or disease | Intervention/treatment |
|---|---|
| Head and Neck Cancer | Genetic: Molecular Analyses |
The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and neck squamous cell carcinoma (SCC).
Additionally, the RESCUE study will contain an exploratory molecular analysis of consenting patients to assess the relationship between cancer genomics, previous radiotherapy, and recurrence in head and neck cancer.
The aim of this study is to determine the survival, functional and quality of life outcomes of patients undergoing all salvage surgery for recurrent, residual and new primary head and neck SCC, and to establish the genetic architecture and clonal evolution H&N SCC after previous treatment for radiotherapy cancer.
| Study Type : | Observational |
| Estimated Enrollment : | 400 participants |
| Observational Model: | Cohort |
| Time Perspective: | Other |
| Official Title: | The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck |
| Actual Study Start Date : | September 8, 2023 |
| Estimated Primary Completion Date : | November 1, 2026 |
| Estimated Study Completion Date : | November 1, 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Head and neck squamous cell carcinoma
| Group/Cohort | Intervention/treatment |
|---|---|
|
Group 1
Participants with previous diagnosis of H&N SCC treated with radiotherapy. Recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx treated with salvage surgery
|
Genetic: Molecular Analyses
Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected. |
Primary Outcome Measures :
- Ascertain the 2-year disease-free survival post salvage surgery [ Time Frame: Study duration is 3 years to include 1 year recruitment period. Active follow-up for patients is up to 2 years. ]Ascertain the 2-year disease-free survival post salvage surgery for recurrent/ residual/ new primary head and neck SCC (split cohort of prospective and retrospective patients)
Secondary Outcome Measures :
- Define the 2- and 5-year overall and disease specific survival in retrospectively identified patients [ Time Frame: Study duration is 3 years to include 1 year recruitment period. Active follow-up for prospective patients is up to 2 years. Follow-up for retrospective patients is up to 5 years. ]Define the 2- and 5-year overall and disease specific survival in retrospectively identified patients undergoing salvage surgery for recurrent/ residual/ new primary head and neck SCC
- Define the 2 year overall and disease specific survival in prospectively identified patients [ Time Frame: Study duration is 3 years to include 1 year recruitment period. Active follow-up for patients is up to 2 years. ]Define the 2 year overall and disease specific survival in prospectively identified patients undergoing salvage surgery for recurrent/ residual/ new primary head and neck SCC
- Report on gross functional outcomes by documenting rates of gastrostomy and tracheostomy dependence at 1-year post-salvage surgery. [ Time Frame: Study duration is 3 years with up to 2 years follow-up in prospective and up to 5 years follow-up in retrospective patients. Functional outcomes will be measured from the date of surgery. ]Report on gross functional outcomes by documenting rates of gastrostomy and tracheostomy dependence at 1-year post-salvage surgery.
- For the prospective cohort assess the overall quality-of-life outcomes pre-operatively and at 6- and 12-months post-surgery using validated questionnaires. [ Time Frame: University of Washing Quality of life questionnaire distributed pre-operatively, 6 months and 12 months. ]For the prospective cohort assess the overall quality-of-life outcomes at pre-operatively and at 6- and 12-months post-surgery using validated University of Washington Quality of Life questionnaire.
- For the prospective cohort assess the swallow-related quality-of-life outcomes at pre-operatively and at 6- and 12-months post-surgery using validated questionnaires. [ Time Frame: MD Anderson Dysphagia Inventory distributed pre-operatively, 6 months and 12 months. ]For the prospective cohort assess the swallow-related quality-of-life outcomes pre-operatively and at 6- and 12-months post-surgery using validated questionnaires.
- Estimate the rates of close and involved surgical margins across all surgical salvage procedures [ Time Frame: Through study completion, expected duration of 3 years ]Estimate the rates of close and involved surgical margins across all surgical salvage procedures
- Determine the impact of close and involved margins on overall survival outcomes [ Time Frame: Through study completion, expected duration of 3 years ]Determine the impact of close and involved margins on overall survival outcomes
- Determine the impact of close and involved margins on disease-free survival outcomes [ Time Frame: Through study completion, expected duration of 3 years ]Determine the impact of close and involved margins on disease-free survival outcomes
- Determine the impact of close and involved margins on disease-specific survival outcomes [ Time Frame: Through study completion, expected duration of 3 years ]Determine the impact of close and involved margins on disease-specific survival outcomes
- Establish the rates of super-selective, selective and modified/ radical salvage neck dissection in clinically N0 and N+ necks [ Time Frame: Through study completion, expected duration of 3 years ]Establish the rates of super-selective, selective and modified/ radical salvage neck dissection in clinically N0 and N+ necks
- Ascertain how the extent of salvage neck dissection influences overall survival outcomes. [ Time Frame: Through study completion, expected duration of 3 years ]Ascertain how the extent of salvage neck dissection influences overall survival outcomes.
- Ascertain how the extent of salvage neck dissection influences disease-free survival outcomes. [ Time Frame: Through study completion, expected duration of 3 years ]Ascertain how the extent of salvage neck dissection influences disease-free survival outcomes.
- Ascertain how the extent of salvage neck dissection influences disease-specific survival outcomes. [ Time Frame: Through study completion, expected duration of 3 years ]Ascertain how the extent of salvage neck dissection influences disease-specific survival outcomes.
- Estimate the rate of occult nodal metastasis in clinically N0 necks with locally recurrent disease [ Time Frame: Through study completion, expected duration of 3 years ]Estimate the rate of occult nodal metastasis in clinically N0 necks with locally recurrent disease
- Describe the impact of neck dissection on overall survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [ Time Frame: Through study completion, expected duration of 3 years ]Describe the impact of neck dissection on overall survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease
- Describe the impact of neck dissection on disease-free survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [ Time Frame: Through study completion, expected duration of 3 years ]Describe the impact of neck dissection on disease-free survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease
- Describe the impact of neck dissection on disease-specific survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [ Time Frame: Through study completion, expected duration of 3 years ]Describe the impact of neck dissection on disease-specific survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease
- Using multi-variate analysis, establish the clinical prognostic indicators of overall, disease free and disease specific survival. [ Time Frame: Through study completion, expected duration of 3 years ]Establish the clinical prognostic indicators of positive survival and functional outcomes
- Using multi-variate analysis, establish the clinical prognostic indicators 12 month tracheostomy and gastrostomy dependence. [ Time Frame: Through study completion, expected duration of 3 years ]Establish the clinical prognostic indicators of functional outcomes
- Compare the DNA genetic and epigenetic changes in residual, recurrent, and new primary head and neck squamous cell carcinoma with primary tumour and germline DNA samples. [ Time Frame: Through study completion, expected duration of 3 years ]Assess the molecular makeup of head and neck tumours that have not responded to radiotherapy treatment, or which recur having previously responded.
Biospecimen Retention: Samples With DNA
Blood, saliva and tumour tissue samples will be collected for analysis as per the protocol.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients diagnosed with recurrent, residual or new primary head and neck SCC following previous treatment with radiotherapy with or without chemotherapy who have undergone or will undergo salvage surgical resection of their cancer. Head and neck subsites including the oropharynx, oral cavity, larynx and hypopharynx will be included. H&N SCC of nasopharyngeal and cutaneous origins, non-SCC, thyroid and salivary gland tumours of the head and neck will be excluded.
Criteria
Inclusion Criteria:
- Aged over 18
- Previous H&N SCC treated with radiotherapy with or without chemotherapy
- Local or regionally recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx
- Ability to give informed consent for biological sample collection (molecular analysis study only)
Exclusion Criteria:
- Nasopharyngeal and cutaneous SCC of the H&N
- Thyroid, salivary gland, and non-squamous cell H&N cancers
- Presence of distant metastasis (M1) or surgically inoperable T4b tumours
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05808920
Contacts
| Contact: Andrew Williamson | 02073528171 ext 1876 | andrew.williamson2@rmh.nhs.uk | |
| Contact: Jeane Guevara | 02073528171 ext 1876 | RESCUE@rmh.nhs.uk |
Locations
| United Kingdom | |
| Head and Neck Unit, Royal Marsden Hospital | Recruiting |
| London, United Kingdom, SW3 6JJ | |
| Contact: Andrew Williamson andrew.williamson2@rmh.nhs.uk | |
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
| Principal Investigator: | Vinidh Paleri | Royal Marsden Hospital NHS Foundation Trust |
| Responsible Party: | Royal Marsden NHS Foundation Trust |
| ClinicalTrials.gov Identifier: | NCT05808920 |
| Other Study ID Numbers: |
CCR 5752 |
| First Posted: | April 12, 2023 Key Record Dates |
| Last Update Posted: | February 7, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site |